Skip to main content
logo
Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
2.330
-0.150 (-6.05%)
May 7, 2026, 1:00 PM EDT - Market open

Company Description

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States.

It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).

The company was founded in 2012 and is headquartered in San Diego, California.

Connect Biopharma Holdings Limited
Connect Biopharma Holdings logo
CountryUnited States
Founded2012
IPO DateMar 19, 2021
IndustryBiotechnology
SectorHealthcare
Employees64
CEOBarry Quart

Contact Details

Address:
3580 Carmel Mountain Road, Suite 200
San Diego, California 92130
United States
Phone877 245 2787
Websiteconnectbiopharm.com

Stock Details

Ticker SymbolCNTB
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$17.00
CIK Code1835268
CUSIP NumberG23549101
ISIN NumberKYG235491019
SIC Code2834

Key Executives

NamePosition
Dr. Barry D. Quart Pharm.D.Chief Executive Officer and Director
David L. Szekeres J.D.President
Lisa Peraza CPASenior Vice President of Finance
Jeff Cohn J.D.General Counsel and Corporate Secretary
Sean T. RistineVice President of Human Resources
Dr. Lei Sun Ph.D.Vice President of Biologics and Head of CMC
Dr. Srikanth Pendyala M.D.Senior Vice President of Clinical Development(Consultant)
Kimberly J. ManhardExecutive Vice President and Chief Development Officer

Latest SEC Filings

DateTypeTitle
Apr 23, 20268-KCurrent Report
Apr 14, 2026SCHEDULE 13GFiling
Apr 1, 2026SCHEDULE 13D/AFiling
Mar 31, 202610-KAnnual Report
Mar 31, 20268-KCurrent Report
Mar 30, 20268-KCurrent Report
Feb 17, 2026SCHEDULE 13G/AFiling
Feb 17, 2026SCHEDULE 13G/AFiling
Feb 17, 2026SCHEDULE 13GFiling
Dec 23, 20258-KCurrent Report
View All SEC Filings